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Abstract: We report a case of an uveal melanoma patient with GNAQ p.Gly48Leu who responded to
MEK inhibition. At the time of the molecular analysis, the pathogenicity of the mutation was unknown.
A tridimensional structural analysis showed that Gαq can adopt active and inactive conformations that
lead to substantial changes, involving three important switch regions. Our molecular modelling study
predicted that GNAQ p.Gly48Leu introduces new favorable interactions in its active conformation,
whereas little or no impact is expected in its inactive form. This strongly suggests that GNAQ
p.Gly48Leu is a possible tumor-activating driver mutation, consequently triggering the MEK pathway.
In addition, we also found an FGFR4 p.Cys172Gly mutation, which was predicted by molecular
modelling analysis to lead to a gain of function by impacting the Ig-like domain 2 folding, which is
involved in FGF binding and increases the stability of the homodimer. Based on these analyses, the
patient received the MEK inhibitor trametinib with a lasting clinical benefit. This work highlights the
importance of molecular modelling for personalized oncology.
Keywords: precision oncology; molecular modelling; mutation; GNAQ; FGFR4
1. Introduction
GNAQ codes for the Gαq cytoplasmic protein, which belongs to the G protein-coupled receptor
family (GPCR) [1]. In its inactive conformation, Gαq binds Guanosine 5′-diphosphate (GDP) and
associates with the two subunits Gβ and Gγ (Figure S1), forming the heterotrimeric G protein, which
binds to the cytoplasmic GPCR transmembrane loops. An external stimulation of GPCR induces
conformational changes in the GPCR transmembrane segments that are transmitted to the bound
heterotrimeric G protein, ultimately promoting the release of GDP in favor of guanosine 5′-triphosphate
(GTP) binding [2]. This activates Gαq which can regulate cellular machinery [3]. Most pathologic
Int. J. Mol. Sci. 2020, 21, 8021; doi:10.3390/ijms21218021 www.mdpi.com/journal/ijms
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mutants involve hotspots of Arg183 and Gln209 in Gαq switch I and II regions, respectively. Both
participate in GDP/GTP interactions (Figure 1a,b). GNAQ or GNA11 mutations are found in >90% of
uveal melanomas, mutually exclusive of one another, most commonly affecting the Gln209 hotspot.
Other recurrently mutated genes in this tumor type are BAP1, SF3B1 and EIF1AX [4–6] (Figure S2).
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representations, respectively. SW-I (183–192), SW-II (206–222) and SW-III (236–246) are, respectively, 
colored in gold, green and salmon (Protein Data Bank, PDB ID 3ohm); (b) zoom on the hotspots 
Arg183 and Gln209 and the active site. Gly48 is colored in orange (PDB ID 3ohm); (c) superimposition 
of the active (grey) and inactive (black) conformations of Gαq/i. SW-I are in yellow/goldenrod, SW-II 
in light-green/dark-green, SW-III in pink/purple. The Gαq active conformation was obtained as a co-
crystal with GDP, AlF4 and Mg2+ (PDB ID 3ohm) [7] and the Gαq/i inactive conformation as a co-
crystal with GDP (PDB ID 3ah8) [8]. 
FGFR4 encodes the protein fibroblast growth factor receptor which is one of the four highly 
conserved transmembrane members of the fibroblast growth factor receptor family (FGFRs) (Table 
S1) The protein structure consists of an extracellular domain (ECD) composed of three 
immunoglobulin-like (Ig-like) domains (D1, D2 and D3), followed by a transmembrane helix and a 
cytoplasmic tyrosine kinase domain. The native ligands of FGFRs are fibroblast growth factors (FGFs) 
that bind to D2 and D3 in the ECD in the presence of heparin or heparin sulfate cofactors. It has not 
Figure 1. Switch regions and hotspots Arg183 and Glu209. (a) Gαq active conformation co-crystallized
with GDP, AlF4 and Mg2+. RAS-like and helical domains are represented in ribbons colored in grey and
blue, respectively. GDP and AlF4 are shown in ball and stick and the Mg2+ in sphere representations,
respectively. SW-I (183–192), SW-II (206–222) and SW-III (236–246) are, respectively, colored in gold, green
and salmon (Protein Data Bank, PDB ID 3ohm); (b) zoom on the hotspots Arg183 and Gln209 and the
active site. Gly48 is colored in orange (PDB ID 3ohm); (c) superimposition of the active (grey) and inactive
(black) conformations of Gαq/i. SW-I are in yellow/goldenrod, SW-II in light-green/dark-green, SW-III in
pink/purple. The Gαq active conformation was obtained as a co-crystal with GDP, AlF4 and Mg2+ (PDB
ID 3ohm) [7] and the Gαq/i inactive conformation as a co-crystal with GDP (PDB ID 3ah8) [8].
FGFR4 encodes the protein fibroblast growth factor receptor which is one of the four highly
conserved transmembrane members of the fibroblast growth factor receptor family (FGFRs) (Table S1)
The protein structure consists of an extracellular domain (ECD) composed of three immunoglobulin-like
(Ig-like) domains (D1, D2 and D3), followed by a transmembrane helix and a cytoplasmic tyrosine
kinase domain. The native ligands of FGFRs are fibroblast growth factors (FGFs) that bind to D2
and D3 in the ECD in the presence of heparin or heparin sulfate cofactors. It has not been clearly
demonstrated if this binding induces the receptor dimerization or if the ligands bind to the receptor
homodimer. This provokes an important conformation change that triggers the intracellular kinase
domain autophosphorylation, which leads to the activation of MAPK, PLCγ and STATs pathways [9].
Int. J. Mol. Sci. 2020, 21, 8021 3 of 12
FGFR members are quite often implicated in various types of cancers and FGFR4 mutations are present
in 6% of melanoma [6].
GNAQ c.142_143delinsTT (p. Gly48Leu) and FGFR4 c.514T > G (p.Cys172Gly) were detected
by next-generation sequencing (NGS) in a subcutaneous metastasis of a patient known to have a
uveal melanoma, and presented in the weekly molecular tumor board (MTB) at Lausanne University
Hospital (CHUV), Switzerland. Since no information existed in the publicly available literature on
their functional significance, the possible impact of these alterations on the respective protein structure
and activity was analyzed by molecular modelling, which predicted a probable activation of both
proteins, supporting a treatment based on MEK inhibitors [10–12]. Thus, a targeted therapy with
trametinib was proposed, which triggered a partial positive response of the patient, stabilizing the
cancer. This result, which constitutes a striking example of a computer-to-bed application of molecular




Gαq’s 3D structure is composed of an α-helical domain and a RAS-like domain which houses
GTPase activity and is required for the Gβγ heterodimer binding (Figure 1a). Three switch regions
(SW-I, SW-II, SW-III) in the RAS-like domain play crucial roles in the protein activity (Figure 1).
Interestingly, GNAQ p.Gly48 corresponds to H/K/NRAS p.Gly12, a famous mutation hotspot in RAS
(Figure S3) [13]. In the inactive conformation of Gαq, SW-I interacts with GDP, while SW-II interacts
with the Gβγ heterodimer. In the active conformation of Gαq, these switches adopt appropriate
positions to bind GTP, leading to a more compact structure (Figure 1c and Figure S4).
Three mutations of Gly48 have been previously identified [6,14–16]. p.Gly48Val was found in
cherry hemangiomas in the presence of a hotspot mutation in position Gln209, and no effect was
attributed to it [17]. The second, which was published after our modelling analysis, is the p.Gly48Leu
mutation itself. It was found in three cases of a hepatic small vessel neoplasm in the absence of other
detected pathogenic or likely pathogenic mutations and was therefore suggested to have a potentially
activating role, although it was not characterized [18]. The third one is the nonsense mutation Gly48*,
which means that no other residue is expressed after position 48, leading to a loss of function as
essential domains are deleted.
Gly48 is a highly conserved residue in many organisms, such as the switch’s regions (Figures S5–S8).
Six experimental structures, Gαq from Mus Musculus, are present in the Protein Data Bank, all of them
in an active conformation. Three other 3D structures contain a guanine nucleotide-binding protein G(i)
subunit alpha-1/guanine nucleotide-binding protein G(q) subunit alpha chimeric protein (Gαi/Gαq)
from Mus Musculus x Rattus Norvegicus. Gαi and Gαq share very similar sequences and functions.
Their overall structural conformations are identical and both catalyze the exchange of GDP to GTP.
The sequence identity between these domains and human Gαq ranges from 94.1 to 99.7% (Figure S9,
Table S2). Furthermore, from the alignment of the structure sequences with human GNAQ, we can see
that even the Gαi/Gαq chimera are highly similar to human sequence as the only alignment difference
is before position 25 based on the human sequence and it does not affect the active site structure, nor
the switch region structures. The totality of the binding site and switch regions are resolved in all
structures used for this study. Structural analysis showed that Gly48 is situated in the active site of
Gαq, close to SW-II. In the inactive conformation, Gly48 is surrounded within 5 Å by Gly46, Thr47,
Glu49, Ser50, Lys52, the GDP phosphate tail, Glu234 and Arg247 (Figure 2a and Figure S10). In the
active conformation, the same residues are found in the vicinity of Gly48, together with other residues
from SW-II: Gly208, Gln209 and Arg213 (Figure 2b and Figure S10). The environment of Gly48 in the
active conformation is more compact and includes SW-II. Due to time limitations in the context of a
molecular tumor board, time-consuming modelling methods such as molecular dynamics simulations
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could not be used to analyse the impact of the mutation on the protein. Hence, we estimated the
impact of the p.Gly48Leu mutation on the folding free energy of the Gαq and Gαi/Gαq structures with
the FoldX software [19], a well-known and efficient program for predicting changes in free energy of
folding upon mutations [20], whose predictive efficiency has been trained on a large set of mutants
covering most of the existing structural environment. This calculation was repeated for all structures,
in the active and inactive conformations, resulting in the folding free energy change upon mutation of
both forms of the proteins. Calculated values are reported in Scheme 1 and Table S3.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 13 
 
of Gly48 in the active conformation is more compact and includes SW-II. Due to time limitations in 
the context of a molecular tumor board, time-consuming modelling methods such as molecular 
dynamics simulations could not be used to analyse the impact of the mutation on the protein. Hence, 
we estimated the impact of the p.Gly48Leu mutation on the folding free energy of the Gαq and 
Gαi/Gαq structures with the FoldX software [19], a well-known and efficient program for predicting 
changes in free energy of folding upon mutations [20], whose predictive efficiency has been trained 
on a large set of mutants covering most of the existing structural environment. This calculation was 
repeated for all structures, in the active and inactive conformations, resulting in the folding free 
energy change upon mutati n of both form  of the proteins. Calculated values are reported in Scheme 
1 and Table S3. 
 
Figure 2. Inactive and active conformations. Residues are shown in sticks, ligands in ball-and-sticks 
and magnesium in sphere representations, respectively. For clarity, residues name in the active 
conformation (PDB ID 3ah8) [8] (b) that are already named in the inactive one (a) are not shown (PDB 
ID 3ohm) [7]. The right part of (a,b) represent the surface of the residues 46–52 and 234–247 to show 
the packing difference between the active and inactive conformations. To clarify, SW-II is not in 
surface representation. SW-I is in yellow/goldenrod, SW-II in light-green/dark-green, and SW-III in 
pink/purple. 
Figure 2. Inactive and active conformations. Residues are shown in sticks, ligands in ball-and-sticks
and magnesium in sphere representations, respectively. For clarity, residues name in the active
conformation (PDB ID 3ah8) [8] (b) that are already named in the inactive one (a) are not shown (PDB
ID 3ohm) [7]. The right part of (a,b) represent the surface of the residues 46–52 and 234–247 to show
the packing differ ce between the active and inactive conformations. To clarify, SW-II is not in surface
represe tation. SW-I is in yellow/goldenrod, SW-II in light-green/dark-green, and SW-III in pink/purple.
These results indicate that mutation p.Gly48Leu is favorable to the structural stability of Gαq
both in the active and inactive conformations. However, the effect is more pronounced in the active
form (1.8 ± 0.7 kcal/mol) than in the inactive one (0.4 kcal/mol). Analyses of the mutant structures
generated by FoldX suggest that p.Gly48Leu active conformation is surrounded by the same residues
as Gly48, plus Glu34 and Arg247 as well as Leu239, Val240 and Glu241 from SW-III. For each active
conformation, the best conformer of the p.Gly48Leu mutant is oriented toward the SW-III region, which
allows hydrophobic interactions with Leu239 and Val240 and thus contributes to stabilizing SW-III
close to the active site, which favors the active conformation. This interaction does not exist in the
inactive conformation of the mutant, where SW-III is too far from Leu48. In the active conformation,
the median distances between Leu48 and Leu239, or Leu48 and Leu249 are 6.3 and 5.3 Å, respectively
(Figure 3, Figures S11 and S12). These median distances are 15.8 and 8.8 Å, respectively, in the inactive
structure. All these findings argue in favor of a possible activation of Gαq as a result of the GNAQ
p.Gly48Leu mutation.
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severe structural impact on Ig-like D2. Multiple sequence alignments of human FGFR4 with orthologs 
show that this position is highly conserved (Figure S13). FGFR4 p.Cys172 is also conserved in the 
whole FGFR family and corresponds to Cys178, -179 and -176 in FGFR1-2 and -3, respectively (Figure 
4c). FGFR1 p.Cys178Ser is already reported in the literature and predicted to lead to a gain of function 
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Figure 3. Distance comparison. (a) Inactive conformation of p.Gly48Leu Gαq mutant (PDB ID 3ah8
modified to introduce the p.Gly48Leu mutation); (b) active conformation of Gly48Leu Gαq mutant
(PDB ID 3ohm [8] modified to introduce the p.Gly48Leu mutation). The SW-III region is colored in
pink and Gly48Leu in orange. Gly48Leu, Leu229 and Val240 are shown in stick representation and the
atoms used for the distance measures are shown as small spheres. (PDB ID 3ah8 [7]). The right parts of
(a,b) represent the surface of the residues 46–52 and 234–247 to show the packing difference between
the active and inactive conformations. To clarify, SW-II is not in surface representation.
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2.1.2. FGFR4 p.Cys172Gly
FGFR4′s structure consists of an extracellular domain (ECD) composed of three
immunoglobulin-like (Ig-like) domains (D1, D2 and D3), followed by a transmembrane helix and
a cytoplasmic tyrosine kinase domain. The native ligands of FGFRs are fibroblast growth factors
(FGFs) that bind to D2 and D3 in the ECD in the presence of heparin or heparin sulfate cofactors. It
has not been clearly demonstrated if this binding induces the receptor dimerization or if the ligands
bind to the receptor homodimer. This leads to an important conformation change that triggers the
intracellular kinase domain autophosphorylation, leading to the activation of the MAPK, PLCγ and
STATs pathways [9].
Structural analysis shows that FGFR4 p.Cys172 is buried in Ig-like D2 in the ECD, and participates
in a disulfide bridge with Cys224 from the same domain. The latter is essential for the structural
stability of D2, which plays a role in FGF binding [21] (Figure 4 and Figure S14). Due to glycine being
unable to reproduce Cys172 interactions, mutation FGFR4 p.Cys172Gly is predicted to have a severe
structural impact on Ig-like D2. Multiple sequence alignments of human FGFR4 with orthologs show
that this position is highly conserved (Figure S13). FGFR4 p.Cys172 is also conserved in the whole
FGFR family and corresponds to Cys178, -179 and -176 in FGFR1-2 and -3, respectively (Figure 4c).
FGFR1 p.Cys178Ser is already reported in the literature and predicted to lead to a gain of function as it
demonstrates a constitutive activation of the FGFR1 dimer state in vitro [22]. Indeed, it was inferred
that this mutation stabilizes the homodimer, favouring the active conformation of the transmembrane
dimers. There is no mutation reported for FGFR4 p.Cys179 and FGFR3 p.Cys176 positions. However,
the recently reported mutation FGFR2 p.His167_Asn173del demonstrated oncogenic transformation
in cells and was therefore predicted to lead to a gain of function [23]. Based on our analysis and
by analogy with mutations FGFR1 p.Cys178Ser and FGFR2 p.His167_Asn173del, mutation FGFR4
p.Cys172Gly is predicted to be an activating mutation that triggers the MEK pathway, similarly to
GNAQ p.G48L.
2.2. Case Description
The patient, a 57-year-old female Caucasian, was diagnosed with uveal melanoma in the posterior
and superior quadrants of the choroid of the right eye in September 2014. Following the eighth
edition of the American Joint Committee on Cancer (AJCC), the tumor was classified as T4cN0M0
and therefore stage IIIB. The size of the tumor was 23.2 × 21.7 mm, with a thickness of 9.6 mm. There
was no ciliary involvement and an extrascleral extension of 4.9 × 4.6 mm, and a thickness of 1 mm,
was detected. The patient received a local therapy by proton beam radiotherapy. In June 2015, three
liver metastases were detected by a control magnetic resonance imaging (MRI), and treated by local
thermal-ablation. The patient progressed in May 2017 with lung, subcutaneous, and liver metastases.
Systemic immunotherapy with the combination of ipilimumab and nivolumab was started. After three
cycles, the patient experienced autoimmune thyroiditis, and the treatment was stopped. The thyroiditis
resolved within a month. The patient then received one additional cycle of nivolumab, complicated
by steroid-resistant autoimmune hepatitis, and the immunotherapy was definitely discontinued. In
October 2017, the patient presented with the progression of subcutaneous nodular lesions, while lung
and liver lesions remained stable. The liver lesions were again treated with thermal-ablation combined
with hepatic radio-embolization. In April 2018, systemic progression and five new brain metastases
were detected. Brain metastases were treated with stereotactic radiosurgery (SRS). Next, an in-house
developed NGS, including the complete exons of 394 cancer-associated genes, was requested on one of
the subcutaneous metastases to identify actionable genomic alterations. Three potentially pathological
mutations were detected: BAP1 c.68-4_84delinsGA (p.?), FGFR4 c.514T > G (p.Cys172Gly) and GNAQ
c.142_143delinsTT (p. Gly48Leu), with allelic frequencies of 82%, 47% and 41%, respectively (Table S4).
Based on the regions covered by our panel, we determined a relatively low tumor mutation burden
(TMB) (2 non-synonymous somatic mutations/Mb), which is typical of uveal melanoma and in part
could explain the absence of response to immune therapy [24,25]. Immunohistochemistry analysis
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showed a PD-L1-negative tumor (Tumor Proportion Score, TPS = 0%). The functional significance of
the GNAQ mutation was described as uncertain in publicly available variant databases.
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Consequently, molecular modelling was requested, which predicted a potential activating role
of the GNAQ mutation. The FGFR4 mutation was considered not targetable by specific FGFR1-3
inhibitors, such as erdafitinib or by non-specific kinase inhibitors such as sorafenib. In addition, we
considered the GNAQ mutation downstream of FGFR activity and hence expected an effect of MEK
inhibition also on FGFR4 signalling. Based on the results of NGS and molecular modelling, the MTB
recommended MEK inhibitor therapy with trametinib at 2 mg/day, every day, which was started in
May 2018. MEK inhibitors have long been tested in uveal melanoma due to the activation of the
MAPK pathway by GNAQ. So far, only a limited efficacy of MEK inhibitors was detected, in immune
therapy naive patients with classical GNAQ mutations [26–28]. Despite the absence of strong clinical
evidence for MEK inhibitors in uveal melanoma and in the absence of other alternative therapies, we
proposed trametinib. An additional reason for prop sing a MEK inhibitor in our im u e therapy
expos patient is that in patients w th NRAS mutant melanoma, MEK inhibitors showed a better
response rate and progression-f ee surviv l (PFS) in i mune therapy-expos d patie ts than in immune
therapy-naïve patients in the NRAS-mutant melanoma (NEMO) trial [29]. The reason for this apparent
difference remains unclear. After two months of treatment, we detected a response (Figure 5). The
patient experienced a grade III mucositis in August 2018, and the treatment had to be suspended for
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one month. During this time, we detected one new brain lesion, which was treated by Stereotactic
Radiosurgery (SRS) (24Gy). In order to avoid further mucositis, the dose of trametinib was halved
(1 mg/day). A repeat MRI showed two more new brain metastases, which, again, were successfully
targeted with SRS (24Gy). After the initial response, the patient maintained a stable disease but
eventually progressed after ten months of treatment, and trametinib was discontinued. Seventy-four
months after the primary diagnosis and 32 months after the presentation of the case in the TBM, the
patient remains alive.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 9 of 13 
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p.Gly48Leu, this mutation-driven activation of FGFR4 could trigger the MEK pathway. 
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treatment for this patient. The fact that the patient had previously been treated with immune therapy 
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experienced patients might respond better to MEK inhibitors and immune therapy than naive 
Figure 5. Positron emission computed tomography scan images. (A,D): Baseline. (B,E): Partial response
(PR) of the patient after 2 months of treatment with trametinib. (C,F): Progression disease (PD) after
10 months of treatment. Arrows indicate the target lesions. Size and standar ized uptake value max
(SUV ax) of the two main lesions, perit eal and left axillary subcutaneous lesion at the different
stages, respectively: (A,D): 2.4 cm/SUV 8.4 and 2 cm/SUV 4.7; (B,E): 2.4 cm/SUV 4.5 and 1. cm/SUV
3.7; (C,F): 6.3 cm/12.2 and .1 cm/SUV 4.8.
3. Discussion
Using molecular modelling, we predicted that mutation GNAQ p.Gly48Leu in protein Gαq
introduces new favorable hydrophobic interactions with SW-III that can maintain SW-III close to
the active site and contributes to maintaining the active conformation of Gαq. On the contrary, this
mutation is predicted to have little or no i pact on the inactive conformation, as SW-III is far from the
active site. Recently, Joseph N.M. et al. [18] hypothesized that mutation p.Gly48Leu could increase
Gαq activity. We agree with their conclusions and established a possible mechanis for this activation.
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Our analysis strongly suggests that GNAQ p.Gly48Leu is a tumor-driver mutation possibly activating
Gαq. In turn, Gαq can activate the MEK pathway via several mechanisms involving PLCβ and
PKC or RasGEF. In addition, we also predicted that mutated FGFR4 p.Cys172Gly likely leads to a
gain of function by stabilizing the homodimer conformation, analogous with what was observed in
FGFR1 p.Cys178Ser and FGFR2 p.His167_Asn173del [22,23]. Similarly to GNAQ p.Gly48Leu, this
mutation-driven activation of FGFR4 could trigger the MEK pathway.
These conclusions contributed to ultimately select a MEK inhibitor, trametinib, as a personalized
treatment for this patient. The fact that the patient had previously been treated with immune therapy
also supported this decision, since, based on the results of the NEMO trial, immune therapy-experienced
patients might respond better to MEK inhibitors and immune therapy than naive patients [29]. At the
end of June 2019, after two months of treatment, the PET-CT (Positron emission tomography-computed
tomography) showed a stable disease with a partial response of some subcutaneous nodules (Figure 5B).
Although the analysis of the GNAQ p.Gly48Leu mutation predicted the activation of the protein
function and consequently of the MEK pathway, strongly supporting the use of trametinib, we cannot
exclude another mechanism by which trametinib might have contributed to stabilize the patient’s
situation, including for instance a possible impact on the tumor microenvironment in melanoma, as
mentioned by Kuske et al. [30].
This work illustrates the importance of molecular modelling analysis in personalized oncology.
Depending on data and resources, it can lead—within the timeframe of the clinical evaluation of
the case—to a valuable prediction of the possible impact of unknown mutations on the structure
and activity of the modified protein, and by extension on the biological pathway involved, helping
clinicians to propose the best treatment for their patients.
4. Materials and Methods
This case report includes a patient from Lausanne University Hospital, Switzerland and was
conducted in accordance with the Declaration of Helsinki, the Swiss legal requirements and the
principles of Good Clinical Practice. The protocol was approved by the Research Ethics Committee
of Canton de Vaud, Switzerland (Protocol No. 2019-00448, 11 February 2020). The patient provided
written informed consent to use her medical information for research purposes and report this case.
The study and the patient treatment were approved by the MTB referents. Further information on
research methods are available in the supplementary information.
For NGS analysis, sections of a formalin-fixed paraffin-embedded (FFPE) biopsy of a subcutaneous
metastasis, containing approximately 80% of tumor cells, were collected for DNA extraction (Maxwell
16 FFPE Plus LEV DNA Purification kit, Promega, Madison WI, USA). Matched constitutional DNA
was extracted from blood (Maxwell 16 LEV Blood DNA kit, Promega). Starting from 100 ng DNA,
capture-based targeted high-throughput sequencing was performed with a KAPA HyperPlus library
preparation kit (Roche, Pleasanton, CA, USA), followed by hybridization capture using a custom design
of xGen Lockdown Probes (Integrated DNA Technologies, Coralville, IA, USA) covering the full-coding
sequences of 394 cancer-associated genes (full list available upon request). Enriched libraries were
sequenced using an MiSeq instrument (Illumina, San Diego, CA, USA). Sequence analysis was based
on established algorithms and pipelines according to the Genome Analysis Toolkit (GATK) standards.
Briefly, forward and reverse reads were aligned to the human genome (GATK repository, build 37
decoy) using BWA-MEM (v0.7.5a). Binary alignment map (BAM) files were subjected to PCR duplicate
removal (Picard v2.1.0), followed by realignment around indels and base recalibration using GATK
tools (v3.7). Single nucleotide variant (SNV) and indel variant calling was performed using samtools
mpileup (v1.9-2) and VarScan (v2.4.3) as well as the MuTect2 algorithm (GATK v3.7) comparing tumor
versus matched normal samples. Raw variant calls were annotated for presence in the dbSNP and
COSMIC databases as well as the mutation effect on gene transcript by SnpEff (v.4.3). SNVs and indels
were filtered based on coverage, quality and variant allele frequency (threshold 5%). Furthermore,
variants were filtered using their biological impact as well as a panel-specific list of known artefacts,
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which were collected during the validation phase of the panel. All retained alterations were confirmed
by visual inspection with IGV software.
UCSF-Chimera (v1.13.1) was used to analyze structures and to measure atom distances [31].
Folding free energies were calculated with FoldX4, which is freely available for academic and non-profit
research institutions [19], with the PositionScan option. Amino acid sequences were retrieved from
UniProt [32,33] and the multiple sequence alignment was performed with Muscle [34]. Gαq structures
were retrieved from the Protein Data Bank (PDB) [35]: 3ah8 [8] (sole inactive conformation), 2bcj [36],
2rgn [36], 3ohm [7], 4gnk [37], 4qj3 [38], 4qj4 [38], 4qj5 [38], 5do9 [39]. The FGFR4 experimental 3D
structure used for the analysis was retrieved from the PDB: 1qct [21].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/21/
8021/s1.
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Abbreviations
AJCC American Joint Committee on Cancer
BAM Binary alignment map
FFPE Formalin-fixed paraffin-embedded
FGF Fibroblast growth factors
FGFR Fibroblast growth factor receptor
Gαi Guanine nucleotide-binding protein G(i) subunit alpha-1
Gαq Guanine nucleotide-binding protein G(q) subunit alpha chimeric protein
GPCR G protein-coupled receptor family
GDP Guanosine 5′-diphosphate
GTP Guanosine 5′-triphosphate
MRI Magnetic resonance imaging
MTB Molecular tumor board
NEMO NRAS-mutant melanoma
NGS Next generation sequencing
PET-CT Positron emission tomography-computed tomography
PDB Protein Data Bank
SRS Stereotactic radiosurgery
SUV Standardized uptake value
SW Switch region
TMB Tumor mutation burden
TPS Tumor Proportion Score
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